# Michael A Letavic

List of Publications by Year
in descending order



| 21 | 945 | 430874 18 | 713466 21 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 21 | 21 | 21 | 926 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Pharmacological characterization of a novel centrally permeable <scp>P2X7</scp> receptor antagonist: <scp>JNJ</scp>â€47965567. British Journal of Pharmacology, 2013, 170, 624-640. | 5.4 | 148 |
| 2 | Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe Epilepsy. Journal of Neuroscience, 2016, 36, 5920-5932. | 3.6 | 127 |
| 3 | Pharmacology of a Novel Central Nervous Systemâ€“Penetrant P2X7 Antagonist JNJ-42253432. Journal of Pharmacology and Experimental Therapeutics, 2014, 351, 628-641. | 2.5 | 67 |
| 4 | A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate. Journal of Medicinal Chemistry, 2018, 61, 207-223. | 6.4 | 58 |
| 5 | Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure Models. PLoS ONE, 2016, 11, e0156468. | 2.5 | 57 |
| 6 | Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. Neuropsychopharmacology, 2018, 43, 2586-2596. | 5.4 | 52 |
| 7 | 4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate. Journal of Medicinal Chemistry, 2017, 60, 4559-4572. | 6.4 | 51 |
| 8 | PET Imaging of the P2X7 Ion Channel with a Novel Tracer [18F]JNJ-64413739 in a Rat Model of Neuroinflammation. Molecular Imaging and Biology, 2019, 21, 871-878. | 2.6 | 50 |
| 9 | Synthesis, SAR, and Pharmacological Characterization of Brain Penetrant P2X7 Receptor Antagonists. ACS Medicinal Chemistry Letters, 2015, 6, 671-676. | 2.8 | 42 |
| 10 | Synthesis and Pharmacological Characterization of Two Novel, Brain Penetrating P2X<sub>7</sub> Antagonists. ACS Medicinal Chemistry Letters, 2013, 4, 419-422. | 2.8 | 40 |
| 11 | A novel radioligand for the ATP-gated ion channel P2X7: [3H] JNJ-54232334. European Journal of Pharmacology, 2015, 765, 551-559. | 3.5 | 40 |
| 12 | Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of <sup>18</sup>F-JNJ-64413739, a PET Radioligand for P2X7 Receptors. Journal of Nuclear Medicine, 2019, 60, 1154-1159. | 5.0 | 36 |
| 13 | Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5( (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor. Journal of Medicinal Chemistry, 2016, 59, 8535-8548. | 6.4 | 35 |
| 14 | Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3157-3163. | 2.2 | 30 |
| 15 | Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. ACS Chemical Neuroscience, 2016, 7, 490-497. | 3.5 | 23 |
| 16 | Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3- a ]pyrazin-8(5 H )-one P2X7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 257-261. | 2.2 | 20 |
| 17 | Selective Inhibition of Orexin-2 Receptors Prevents Stress-Induced ACTH Release in Mice. Frontiers in Behavioral Neuroscience, 2017, 11, 83. | 2.0 | 20 |
| 18 | P2X7 receptor antagonists for the treatment of systemic inflammatory disorders. Progress in Medicinal Chemistry, 2020, 59, 63-99. | 10.4 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Substituted 5,6-(Dihydropyrido[3,4-d]pyrimidin-7(8H)-yl)-methanones as P2X7 Antagonists. ACS Chemical Neuroscience, 2016, 7, 498-504. | 3.5 | 17 |
| 20 | 1H-Pyrrolo[3,2-b]pyridine GluN2B-Selective Negative Allosteric Modulators. ACS Medicinal Chemistry Letters, 2019, 10, 261-266. | 2.8 | 9 |
| 21 | Design, Synthesis, and Preclinical Evaluation of 3-Methyl-6-(5-thiophenyl)-1,3-dihydro-imidazo[4,5-b]pyridin-2-ones as Selective GluN2B Negative Allosteric Modulators for the Treatment of Mood Disorders. Journal of Medicinal Chemistry, 2020, 63, 9181-9196. | 6.4 | 5 |